ARTICLE | Company News
Genaera inflammation, dermatology news
January 18, 2010 8:00 AM UTC
Genaera's remaining assets will be liquidated, with bids to be received no later than Feb. 12. The assets include Genaera's interest in MEDI-528, a mAb against interleukin-9 (IL-9) in Phase II testi...